CityU develops new technology for about 10,000 yuan to draw blood to test early cancer, but the source must be found separately

Social News

Written by: Deng Yinglin

2019-12-19 12:08

At present, Hong Kong mostly uses imaging tests and surgical extraction of tumor tissue tests of patients to detect cancer. The biomedical research team of the City University of Hong Kong announced today (19th) that a new detection technology has been developed. After clinical comparison tests, it was found that only about 4 Milliliter of blood can sort out cancer cells in about five minutes. If the sample is found to contain 4 or more cancer cells, there is a greater chance of cancer. The team stated that the accuracy rate of detecting cancerous fats can be as high as 90%. The examination at this stage failed to reflect the source of the cancer cells, that is, the source of the disease could not be found in the same examination.

Yu Weijian, senior associate researcher at CityU's Department of Biomedicine, pointed out that the new technology developed by the team can isolate blood cells and screen cancer cells in five minutes to detect early cancers. (Photo by Deng Yinglin)

Research team members include Zou Heng and Yu Weijian, senior associate researchers in the Department of Biomedical Sciences of CityU. They pointed out that the breakthrough cancer early screening and disease monitoring technology developed by the team can detect cancer 3 to 6 months earlier than imaging examination, and even tumors as small as 0.1 mm can be detected, which is the fastest technology in the world with the same principle.

In addition to being diagnosed with cancer in a short period of time, the test can also monitor the efficacy of the drug in the course of treatment, test whether the patient is resistant to the drug, and analyze early if there is a need to change the drug or change the cancer treatment plan. The relevant technology is licensed to the start-up company "Jingzhun Biopharmaceutical Group Co., Ltd." established by the team in 2017. The product has been certified by the State Food and Drug Administration (NMPA) of China and is expected to receive the EU in vitro diagnostic medical device (IVDD) next month. CE certification.

1 drop of urine test for 15 types of cancer! New technology will be launched next year, "zero period" knows the accuracy rate is more than 80%

[Lung cancer treatment] Third-line EGFR lung cancer target drugs may be considered for first-line treatment

[Medical examination] 3 kinds of tests found that early cancer has a family history of high risk and early cancer test index

City University Cancer